Why This Question Matters More Than Ever

Every week in my clinics at Banjara Hills and Madeenaguda, patients slide a printed WhatsApp screenshot across my desk. It shows a Facebook post from a well-meaning relative explaining that "PRP is not proven" — or conversely, from a private wellness centre claiming it "regenerates cartilage completely." Neither is accurate. The truth, as always, lives in the primary literature and the expert consensus documents — and in 2024, that truth shifted meaningfully in PRP's favour.

Knee osteoarthritis (KOA) affects roughly 23% of adults over 40 worldwide. In Hyderabad's IT corridor, I see a specific phenotype: the 42-year-old software engineer whose knee cartilage has been silently eroding for years — partly from a sedentary desk lifestyle, partly from the jarring impact of our city's legendary potholes on weekend motorbike rides. For these patients, the window between "early OA" and "you need a replacement" is exactly where evidence-based regenerative medicine lives — and where PRP, used correctly, can be genuinely transformative.

What Is PRP and Why Does It Work? The Biology in Plain Language

Platelet-rich plasma (PRP) is prepared from your own blood — typically 15–60 ml drawn from a vein in your arm — which is then centrifuged to separate and concentrate the platelets. Normal blood contains roughly 150,000–400,000 platelets per microlitre; a well-prepared PRP concentrate delivers 3–8× that amount into a small volume of plasma.

Why does this matter for an arthritic knee? Platelets are the body's first-responder repair cells. When activated, they release a cascade of bioactive signalling proteins — including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Vascular Endothelial Growth Factor (VEGF), and Insulin-Like Growth Factor-1 (IGF-1). These growth factors do three things in an osteoarthritic joint: they suppress the inflammatory cytokines (IL-1β, IL-6, TNF-α) that are actively dissolving cartilage matrix; they stimulate the synovial lining to produce healthier, more viscous joint fluid; and they signal chondrocytes (cartilage cells) toward repair rather than apoptosis (self-destruction).

The important distinction that drives all the guideline debates is between Leukocyte-Poor PRP (LP-PRP) and Leukocyte-Rich PRP (LR-PRP). LP-PRP strips out most of the white blood cells before injection, delivering a clean, anti-inflammatory growth factor concentrate. LR-PRP retains white cells, which bring additional inflammatory mediators into an already inflamed joint space. For intra-articular use in OA, the current evidence consistently favours LP-PRP — and this is the formulation protocol we use at IBAP Clinics.

International Society Positions — The Definitive Breakdown

The landscape of society guidance is more nuanced than most patients — or indeed many clinicians — appreciate. Below is a society-by-society analysis of the current positions, with the key nuances that determine whether a "recommendation against" is a verdict on safety or simply a call for better standardisation.

ESSKA–ICRS Joint Consensus 2024: The Gold Standard

The most clinically significant development of 2024 was the publication of the joint consensus by the European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) and the International Cartilage Regeneration and Joint Preservation Society (ICRS). Using the rigorous RAND/UCLA Appropriateness Methodology — the same framework used by NHS NICE in the UK — a panel of leading orthopaedic scientists from across Europe evaluated 216 distinct clinical scenarios combining patient age, disease severity, previous treatment history, and joint effusion status.

The verdict: PRP injections are considered appropriate in patients aged 80 years or younger with knee KL grades 0–III after failure of conservative non-injective or injective treatments. The recommendation carries a Grade I evidence classification. Of the 216 scenarios analysed, 84 (38.9%) were rated appropriate, only 9 (4.2%) inappropriate, and the remainder uncertain — with the highest uncertainty appropriately clustered around KL Grade IV (bone-on-bone) disease and use as a first-line treatment.

ESSKA ORBIT Consensus 2024: Three Grade A Pillars

Separately — but complementarily — ESSKA's ORBIT (OrthoBIologics InitiaTive) working group published a dedicated review of blood-derived products for knee OA in early 2024. Twenty-eight question-statement sets were evaluated. Three received the coveted Grade A designation — meaning support from the highest levels of scientific literature: (1) that there is sufficient preclinical and clinical evidence to support PRP use in knee OA; (2) that PRP is effective in mild-to-moderate KOA (KL ≤ 3); and (3) that LP-PRP is the preferred intra-articular formulation.

AMSSM — The Sports Medicine Voice (2021)

The American Medical Society for Sports Medicine (AMSSM) published its position statement on regenerative medicine and orthobiologics in 2021 under the leadership of Dr Jonathan Finnoff, Chief Medical Officer of the US Olympic and Paralympic Committee. The statement supports the responsible clinical introduction of PRP, advocates for biological quality control and standardised Patient-Reported Outcome Measures, and explicitly recommends dedicated expertise and equipment for optimal results. This is not a lukewarm equivocation — it is a framework for clinical excellence that validates PRP as a legitimate therapeutic option in sports medicine.

AAOS — The Limited Positive (2021)

The American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guideline on Surgical Management of OA of the Knee assigns PRP a "Limited" recommendation. In AAOS grading, "Limited" is the lowest positive tier — meaning the evidence supports benefit but lacks consistency or sufficient quantity to elevate to "Moderate" or "Strong." Critically, this is not a recommendation against — it is a positive grade held back by heterogeneous preparation protocols rather than negative clinical outcomes.

ACR and OARSI — Understanding the "Against" Vote

The American College of Rheumatology (ACR) and Osteoarthritis Research Society International (OARSI) currently issue recommendations against PRP for knee OA. It is essential to understand what this means — and what it does not mean. Neither society found evidence of harm. Both explicitly cite the lack of standardised PRP preparation protocols as the methodological barrier. OARSI, for instance, uses a rigorous evidence framework that requires consistent product definitions across trials; when 40 different commercially available PRP systems produce 40 different platelet concentrations and leukocyte profiles, pooled meta-analysis becomes mathematically unreliable regardless of clinical signal. This is a measurement problem, not an efficacy problem.

The ACR's "conditional" prefix is equally telling — a conditional recommendation, by ACR's own methodological definition, means the evidence is uncertain enough that patient-specific factors and preferences should guide the decision. It is not the categorical veto it is sometimes presented as.

NICE (UK, 2019) — Governance Without Prohibition

NICE issued Interventional Procedure Guidance IPG695 on PRP for knee OA in 2019. The guidance notes no major safety concerns but describes evidence on efficacy as "limited in quality." NICE recommends the procedure should be used only with "special arrangements for clinical governance, consent, and audit or research" — essentially placing PRP in the "emerging technology requiring careful tracking" category rather than condemning it. Post-2024, given the ESSKA-ICRS Grade I evidence, a revision of NICE guidance is anticipated by many UK pain and orthopaedic specialists.

French Francophone Expert Consensus

A group of French-speaking experts issued a national consensus statement recommending PRP as a second-line injectable treatment for knee OA after failure of first-line pharmacological and non-pharmacological approaches. France also has a particular clinical research advantage: the Marseille-based Assisted Public Hospital AP-HM operates a dedicated regenerative medicine programme with rigorous biological quality control, publishing real-world outcome data that has been instrumental in the European evidence base.

Global Reimbursement — Country by Country

Reimbursement decisions are often misunderstood as clinical verdicts. They are not — they are economic and regulatory decisions, influenced by healthcare system structures, available budget, HTA methodology, and political priorities. Nevertheless, where a public health system covers a treatment, it signals meaningful institutional confidence in the evidence base. Here is the verified landscape as of mid-2026.

How PRP Compares to Other Knee Injections

Patients often ask me: "Why not just have a steroid injection, doctor? It's cheaper and covered by insurance." The answer lies in the biological direction of travel. Think of it this way: a steroid injection is like turning down the fire alarm in a burning building — the noise stops, but the fire continues. PRP is more like sending in a construction and repair crew, along with some fire suppressants, to address the underlying structural problem.

One of the most important clinical insights from the published literature is the temporal pattern. Corticosteroids win on speed — a patient flaring badly before a wedding in two weeks benefits enormously from a well-timed steroid injection. PRP is the opposite: its onset is slower (4–6 weeks) but its arc of benefit is substantially longer, and critically, it does not carry the risk of accelerating cartilage loss with repeated administration. For a 45-year-old Hyderabad software professional who wants to stay active for the next 15–20 years before potentially needing a replacement, the risk-benefit calculation strongly favours PRP as the long-term strategy.

Who Benefits Most From PRP at IBAP Clinics

Not every knee is a PRP knee. In my practice, the ideal PRP candidate presents with a fairly consistent profile: moderate knee pain (VAS 4–7/10) that has not responded adequately to physiotherapy, weight management, and NSAIDs; imaging showing KL grade I–III changes without complete joint space obliteration; a body mass index under 35; no active inflammatory arthritis (rheumatoid, psoriatic, crystal arthropathy); and a willingness to commit to post-injection rehabilitation.

Patients who have come from distant areas of Hyderabad — or even from cities like Warangal and Vijayawada — often ask whether a single injection will suffice. Here the evidence is interesting: the French registry data (Marseille AP-HM, 2024) demonstrated significant benefit from a single high-volume very-pure PRP injection at 18 months in a carefully selected cohort. However, the preponderance of evidence and the ESSKA ORBIT consensus support a minimum of 3 injections as the standard course. We tailor the protocol to the individual.

Key Evidence Milestones — Landmark Trials and Meta-Analyses